

# Optimizing Injectable in situ Forming Implants for Sustained Release of Ophthalmic Therapeutics

Valerie Eta D. Sc (Tech)



INTEGRATING  
**Delivery Science**  
ACROSS DISCIPLINES

REBIO  
PHARMA




# Optimizing Injectable *in situ* Forming Implants for Sustained Release of Ophthalmic Therapeutics

Standard of care treatments in the eye have been daily drops or regular injections



Rebio's SiSu® technology can deliver a broad range of APIs for up to 6 months with a single treatment




ReBio's focus on Subconjunctival and Intravitreal dosing

## ReBio's SiSu® In Situ Forming Implant Technology

- PLGA-based phase-inverting anhydrous liquid polymer platform
- Release effective levels of therapeutics locally

# Effect of PLGA composition on Prostaglandin drug release

## In Vitro dissolution



→ adjustable drug release In Vitro

# Prostaglandin Analogue Drug – Intravitreal Implant


Day 0

1 month

2 months


3 months

> 7 months




→ *In vitro - In vivo* correlation

**In Vitro - Prostaglandin daily release**



**In Vivo - Prostaglandin AH concentration**




# Post Operative Healing (1 cm Incision Just Above Limbus) Sub-Conjunctival Corticosteroid SiSu® Injection - Rabbit


Day 0



2 months



3.5 months



**REBIO**  
PHARMA

Poster No. 886

Thank You

**REBIO**  
PHARMA

Sustained Treatment  
for Chronic Eye Diseases

